Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Pamine Generic Name & Formulations
Legal Class
Rx
General Description
Methscopolamine bromide 2.5mg; tabs; lactose-free.
Pharmacological Class
Anticholinergic.
See Also
How Supplied
Tabs—100; Forte—60 (5x12 blisters)
Manufacturer
Pamine Indications
Indications
Adjunctive therapy in peptic ulcer.
Pamine Dosage and Administration
Adult
Initially 2.5mg 30min before meals and 2.5–5mg at bedtime; may increase as tolerated. Severe symptoms: may start at 5mg 30min before meals and at bedtime.
Children
Not established.
Pamine Contraindications
Contraindications
Glaucoma. Obstructive uropathy (eg, bladder neck obstruction due to prostatic hypertrophy). GI obstruction (eg, pyloroduodenal stenosis). Paralytic ileus. Intestinal atony in elderly or debilitated. Unstable cardiovascular status in acute hemorrhage. Severe ulcerative colitis. Toxic megacolon complicating ulcerative colitis. Myasthenia gravis.
Pamine Boxed Warnings
Not Applicable
Pamine Warnings/Precautions
Warnings/Precautions
Ileostomy or colostomy. Autonomic neuropathy. Hepatic or renal disease. Ulcerative colitis. Hyperthyroidism. Coronary heart disease. CHF. Tachyrhythmia. Tachycardia. Hypertension. Prostatic hypertrophy. Large doses may suppress intestinal motility or aggravate toxic megacolon. Follow-up with upper GI contrast radiology or endoscopy during treatment. Obtain stool tests, hemoglobin, and hematocrit to rule out ulcer bleeding. High environmental temperature. Elderly. Pregnancy (Cat.C). Nursing mothers.
Pamine Pharmacokinetics
See Literature
Pamine Interactions
Interactions
Additive anticholinergic effects with concomitant antipsychotics, tricyclic antidepressants, and other anticholinergic drugs. Concomitant antacids may interfere with absorption.
Pamine Adverse Reactions
Adverse Reactions
Tachycardia, palpitation, anaphylaxis, headache, nervousness, drowsiness, dizziness, blurred vision, pupil dilation, loss of taste, urinary hesitancy/retention, nausea, vomiting, constipation, decreased sweating, urticaria, xerostomia, weakness, insomnia, impotence, lactation suppression.
Pamine Clinical Trials
See Literature
Pamine Note
Not Applicable
Pamine Patient Counseling
See Literature
